Screener
Tyra Biosciences, Inc. TYRA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Prepaid expenses and other assets | (2,438) | (2,667) |
| Accounts payable, accrued expenses and other liabilities | 1,195 | (365) |
| Right-of-use assets and lease liabilities, net | 17 | 22 |
| Net cash used in operating activities | (32,571) | (25,458) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (162,206) | (6,870) |
| Maturities of marketable securities | 42,050 | 38,910 |
| Purchases of property and equipment | (88) | (14) |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s operating cash flow?
- Tyra Biosciences, Inc. (TYRA) reported operating cash flow of -$32.57M in Q1 2026.
- How has Tyra Biosciences, Inc.'s operating cash flow changed year-over-year?
- Tyra Biosciences, Inc.'s operating cash flow decreased by 27.9% year-over-year, from -$25.46M to -$32.57M.
- What is the long-term trend for Tyra Biosciences, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s operating cash flow has grown at a 41.5% compound annual growth rate (CAGR), from -$23.75M to -$95.14M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Tyra Biosciences, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude